Ultherapy PRIME and Earlier Generations: What Changed and What Did Not

The Ultherapy generation timeline

Ultherapy is not a single fixed device. It began as the Ulthera System, authorized by the FDA in 2009, and moved through a series of clearances that widened its cleared uses and, most recently, modernized the console as Ultherapy PRIME in 2024. Across that span the core method stayed the same: micro-focused ultrasound delivered at set depths with an imaging step. For a clinic buying, servicing, or verifying a system, the question that matters is which generation is in the room, because the generation sets both the regulatory record it falls under and the transducers it supports.

How the cleared uses grew

The indication set widened in steps rather than all at once. The original 2009 authorization covered a brow lift, which was enough to create a new device category through the De Novo route. A 2012 clearance added lifting of lax tissue under the chin and on the neck. In 2013 the imaging function was cleared, which is why visualization is part of the modern system rather than an add-on. A 2014 clearance added the appearance of lines and wrinkles on the upper chest. Reading the timeline this way helps a clinic understand why an older console may carry a narrower set of cleared uses than a current one, even though the underlying method is shared.

What Ultherapy PRIME changed

Ultherapy PRIME, cleared in 2024, is a console update. It modernized the hardware and the operator interface while keeping the same cleared indications as the system it replaced. A model revision followed in 2025. The distinction matters for how a clinic reads marketing around PRIME: the change is to the platform and workflow, not to what the device is cleared to treat. Treating PRIME as a new set of clinical claims would overstate the clearance. The practical gains a clinic sees from PRIME are in the console experience and workflow rather than in a wider treatment scope.

Ulthera, Ultherapy, and the naming question

Two names circulate for the same platform, and the difference trips up clinics doing their checks. Ulthera is the company, and it is the name under which the device is filed in FDA records. Ultherapy is the treatment trademark used in marketing. A clinic checking regulatory status should search Ulthera, because the trademark name returns no records in the device database. Some older listings also reference Ulthera SPT; SPT appears in earlier system naming and is not detailed in the FDA clearance records reviewed for this guide, so treat it as a label to confirm with the seller rather than a defined specification.

Transducer compatibility across generations

Because the platform changed over time, transducers are matched to the console generation rather than being universal. A transducer supported on one generation is not necessarily supported on another, so confirm the model against the specific console before ordering. Compatibility is based on industry-standard usage and clinical experience, so verify against your specific system. Pinova lists professionally sourced transducers compatible per Ultherapy generation, and the selection detail sits in the guide to Ultherapy transducers.

What this means for clinics buying or verifying a system

When a practice evaluates a used or transferred system, the generation determines both the clearance it falls under and the consumables it can run. The steps are practical: identify the generation from the console and documentation, match the FDA record under Ulthera, and confirm transducer support before committing. The purchase side is covered in the guide to buying an Ultherapy console, and the authentication steps are in verifying the system generation. The current clearance record for PRIME can be checked in the FDA 510(k) database.

Frequently asked questions

What is Ultherapy PRIME?

Ultherapy PRIME is the current console version, cleared by the FDA in 2024. It updated the hardware and interface while keeping the same cleared indications as earlier Ultherapy systems.

Is Ultherapy PRIME different from earlier Ultherapy?

The platform and interface changed; the cleared uses did not. PRIME treats the same indications as the system it replaced, so the difference is in workflow and hardware rather than clinical scope.

Is Ulthera the same as Ultherapy?

Yes. Ulthera is the company and FDA filing name; Ultherapy is the treatment trademark. Both refer to the same platform.

What is Ulthera SPT?

SPT appears in earlier system naming and is not detailed in the FDA clearance records reviewed here. Treat it as a label to confirm with the seller rather than a defined specification.

When was Ultherapy first cleared?

The original Ulthera System was authorized in 2009 through a De Novo pathway, which created the focused ultrasound device category. Later clearances added indications and updated the console.